Navigation Links
Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
Date:7/20/2009

CHAPEL HILL, N.C., July 20 /PRNewswire/ -- Today's physicians are losing influence over patients' drug utilization decisions. Now, a large number of bio-pharmaceutical companies control the vast majority of prescription drug expenditures. Continued formulary access depends largely on a company's ability to evolve its MMMR (Managed Markets Market Research) structures to work effectively in the current payer-driven environment.

Best Practices, LLC initiated research to assist leaders of Market Research and Managed Markets in identifying tactics and success factors for understanding and acting upon the needs of third-party payers. A well-structured MMMR group facilitates a relationship between bio-pharma and third-party payers that offers competitive advantage to both parties.

Sample key findings that emerged from this research are the following:

  • Don't Wait Until It's Too Late to Develop MM Insights: MMMR activities peak during Phase 3, though most benchmark partners are moving to push these into earlier phases. This may prove most viable for breakthrough medicines where pharmacoeconomic differences can be identified, and may prove less effective for me-too drugs, as pushing research earlier may give payers more time to develop strategies against undifferentiated products.
  • Performance Guarantees/Warranties: Eighty percent of benchmarked companies have explored the concept of offering warranties, but most find their usefulness limited due to unpredictable patient compliance and complex Medicaid-related CMS submissions. The warranty concept seems best applied for novel drugs in unique therapeutic categories where Medicaid is not a major payer.

This report is based on an analysis of survey results and interview content collected from 11 participating companies including Abbott Labs, Alcon, Amgen, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Novo Nordisk, Sepracor, Solvay, Ther-Rx and Xanodyne Pharmaceuticals.

A Report excerpt, "Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights", is available at http://www3.best-in-class.com/ or copy and paste the following URL in your browser http://www3.best-in-class.com/rr983.htm

For more information, on Best Practices, LLC's research and services, contact Cameron Tew, Executive Director at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Campaign to Increase the Awareness and Understanding of Lou Gehrigs Disease Reaches 22 U.S. States
2. New Survey Reveals Gap in Understanding of Alzheimers Disease Risk and Prevention Among Most Vulnerable Populations
3. Immtech and Beijing Pharmaceutical Group Co. Sign Memorandum of Understanding to Explore Developing Strategic Business Alliance
4. Understanding the science of solar-based energy: more researchers are better than one
5. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
6. Scientists fix bugs in our understanding of evolution
7. Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine
8. March of Dimes Awards $250,000 Prize to Leaders in Understanding Embryonic Development
9. Understanding of actuator properties of carbon nanotubes bring micro machines closer
10. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
11. URAC Director of Pharmacy Programs to Speak at Academy of Managed Care Pharmacy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 A Europe-wide survey of ... researchers using animals in their research treat them with due care. ... and detailed analysis of the results indicates that there is a ... to put into practice the principles of the 3Rs (Refine, ... What ...
(Date:2/27/2017)... Feb. 27, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the U.S. Food and Drug Administration (FDA) has ... section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual ... with moderate-to-severe acute pain in a medically supervised ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire ... grandfather, “Hire for attitude. Train for skill.” , In keeping with this philosophy, the ... as a salesman. Zamzow is hoping to replicate the practice throughout the company. , ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):